A federal judge in Minnesota denied a motion for class certification by drug wholesalers in a lawsuit accusing EpiPen manufacturer Mylan of overcharging for the medication in an alleged racketeering scheme, concluding that the plaintiffs failed to satisfy certification requirements, including numerosity and commonality.